Indivior Share News (INDV)

LONDON BROKER RATINGS: KBW cuts Aviva 'market perform'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Indivior raises 2023 guidance after strong half-year progress

(Alliance News) - Indivior PLC on Thursday celebrated a strong recent six months and second quarter that brough increased profit and revenue, boosting its optimism for the rest of the year.

Indivior lifts guidance after strong first half

(Sharecast News) - Pharmaceuticals firm Indivior reported a 24% improvement in net revenue in its half-year report on Thursday, to $529m.

LONDON BRIEFING: Shares on the rise; Frasers buys into AO World

(Alliance News) - Stocks in London were set to open higher on Monday, at the start of a busy week of central bank moves.

Indivior reaches settlement in litigation with US states

(Sharecast News) - Addiction treatment-focussed pharmaceuticals company Indivior announced on Monday that its subsidiary Indivior Inc has successfully reached an agreement to resolve the claims brought against it by the attorneys general of 41 US states and the District of Columbia.

Indivior settles antitrust claims in US regarding Suboxone drug

(Alliance News) - Indivior PLC on Friday said it has reached an agreement to resolve the claims brought in antitrust multi-district litigation regarding its drug Suboxone.

LONDON BROKER RATINGS: Numis starts Tristel with 'add'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Indivior emergency opioid overdose treatment approved by US FDA

(Alliance News) - Indivior PLC on Tuesday said the US Food & Drug Administration has approved its OPVEE nasal spray for the emergency treatment of opioid overdose.

Indivior's opioid addiction sprat approved by FDA

(Sharecast News) - US health regulators have approved Indivior's Opvee nasal spray treatment for opiod addiction, the company said on Tuesday.

DIRECTOR DEALINGS: Indivior division chief sells GBP1.7 million shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Wednesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

Indivior lifts revenue guidance, cuts profit outlook after Opiant deal

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its full-year revenue guidance on Thursday but trimmed its outlook for operating profit due to costs related to the acquisition of Opiant Pharmaceuticals, as it posted a jump in first-quarter profit and revenue.

Indivior raises 2023 revenue forecast following Opiant acquisition

(Alliance News) - Indivior PLC on Thursday said net revenue increased by more than 20% in the first quarter, lifting profit, and it updated its guidance for the year following its acquisition of Opiant Pharmaceuticals Inc last month.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Indivior completes acquisition of Opiant Pharmaceuticals

Indivior PLC - North Chesterfield, Virginia-based pharmaceutical company - Completes the acquisition of Opiant Pharmaceuticals Inc. Says the acquisition will strengthen its addiction treatment and science portfolio through the addition of Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment.